Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aclaris Therapeutics Inc.

Topical treatment for benign but aesthetically bothersome growths

This article was originally published in Start Up

Executive Summary

Aclaris Therapeutics Inc. is developing a topical treatment for seborrheic keratosis, a type of benign growth typically described as a cross between a lesion and a tumor. As envisioned, the preparation that the company now calls A-101 might not only provide an alternative to surgery, but also may be straightforward enough to be applied by non-physician staff.

You may also be interested in...



Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine

The latest drug development news and highlights from our US FDA Performance Tracker.

Skin Is In With Biomedical Investors

Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.

Super-Specialist CROs: Commercializing Pharma R&D Expertise

Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel